Skip to content

April 29, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Manufacturing
The strategic investments expanding CDMO capabilities for HPAPIs and ADCs

Manufacturing

The strategic investments expanding CDMO capabilities for HPAPIs and ADCs

Pharmaceutical Technology

Demand for HPAPIs and ADCs is accelerating, prompting CDMOs to invest to strengthen manufacturing capabilities for oncology.

Read full story

pharminent April 29, 2026 (Last updated: April 29, 2026)

Pharmaceutical Technology

Demand for HPAPIs and ADCs is accelerating, prompting CDMOs to invest to strengthen manufacturing capabilities for oncology.

Read full story

Post navigation

Previous: Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies

Next: Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact

Related Stories

Manufacturing

Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus

pharminent April 23, 2026

Manufacturing

AbbVie opts for North Carolina to house $1.4bn manufacturing site

pharminent April 23, 2026

Manufacturing

AbbVie makes record investment in North Carolina plant

pharminent April 23, 2026

You May Have Missed

Commercial

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

pharminent April 29, 2026

Regulatory

AZ, Amgen will pilot FDA’s real-time clinical trial plan

pharminent April 29, 2026

Regulatory

AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions

pharminent April 29, 2026

Commercial

Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’

pharminent April 29, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.